肺癌患者中医证候分型与T淋巴细胞亚群及NK细胞的相关性研究

Study on the Relationship between the Traditional Chinese Medicine Differentiation of Lung Cancer and T Lymphocyte Subsets and Natural Killer Cells

目的:探讨肺癌中医证型与细胞免疫功能的相关性。方法:选择肺癌患者219例,辨证分型为气滞血瘀、痰瘀蕴结、痰热蕴肺、阴虚毒热、气阴两虚、肺脾气虚、肺肾两虚型。并对肺癌患者的T淋巴细胞亚群及NK细胞标志物CD(16+56)+进行检测。结果:肺癌患者CD3+、CD4+、CD4+/CD8+、CD(16+56)+均显著低于正常组(P<0.01或P<0.05);实证患者的CD3+、CD4+均显著高于虚证组(P<0.01);阴虚毒热、气阴两虚、肺脾气虚、肺肾两虚的外周血CD3+、CD4+均明显低于气滞血瘀证、痰瘀蕴结证(P<0.01或P<0.05);KPS≥60肺癌患者CD3+、CD4+明显高于KPS<60患者(P<0.01);肺癌患者ZPS的评分越高,其CD3+、CD4+越低(P<0.01)。结论:肺癌患者的中医证型与细胞免疫功能具有相关性,可能为肺癌临床辨证治疗提供较为客观的免疫学指标。

Objective：To investigate the relation ship between the Traditional Chinese differentiation in patients of lung cancer and the cell immunity function. Method：To proceed diagnesis and diferentiation in TCM, there are Qi stagnation and blood stasis, Accumulation of phlegm and stagnation, Accumulation of phlegm and heat in lung, Yin asthenia and virulent heat, Asthenia of both Qi and Yin, Asthenia of both lung and spleen,Asthenia of both lung and kidney. To analyze the T lymphocyte subsets and CD（ 16 ＋ 56） ＋ of NK cell for 219 cases of lung cancer. Results： CD3^＋ , CD4^＋ ,CD4^＋/CD8^＋ ratio, CD（ 16 ＋ 56）^＋ decreased significantly in lung cancer group as compared with normal group（P〈 0. 01 or P〈 0.05）. CD3^＋ , CD2 decreased significantly in Asthenia syndrome of lung cancer group as compared with sthenia syndrome（ P 〈 0.01 ）. CD3^＋ , CD4^＋ decreased significantly in Yin asthenia and virulent heat, Asthenia of both qi and yin,Asthenia of both lung and spleen,Asthenia of both lung and kidney syndrome of lung cancer as compared with Qi stagnation and blood stasis, Accumulation of phlegm and stagnation syndrome（P〈 0.01 or P〈0.05）. CD3^＋ ,CD4^＋ increased significantly in lung cancer sufferer of KPS 60 as compared with KPS〈60 group （P〈0.01）. ZPS of lung cancer sufferer is more high,CD3^＋ ,CD4^＋ is more low （P 〈 0.01 ）. Conclusion：The Traditional Chinese differentiation and cell immunity function of the lung cancer sufferer have relativity, the possibility provides more objective immunology index sign for the lung cancer clinical treatment based on syndrome differentiation.